Compendium of Cancer Genome Aberrations

HAEM5:ALK-positive large B-cell lymphoma: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
Undo revision 14817 by Bailey.Glen (talk)
Tag: Undo
Line 1: Line 1:
{{DISPLAYTITLE:ALK-positive large B-cell lymphoma}}
{{DISPLAYTITLE:ALK-positive large B-cell lymphoma}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]


{{Under Construction}}
{{Under Construction}}
Line 7: Line 7:
}}</blockquote>
}}</blockquote>


<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click nearby within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>


==Primary Author(s)*==
==Primary Author(s)*==
Line 88: Line 88:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)||<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
<span class="blue-text">EXAMPLE:</span> 30% (add reference)
EXAMPLE 30% (add reference)
|Yes
|Yes
|No
|No
|Yes
|Yes
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
Line 99: Line 99:


<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the previous version of the page. Please incorporate above.}}


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 151: Line 151:
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==


Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 161: Line 161:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


7
7
|<span class="blue-text">EXAMPLE:</span> Loss
|EXAMPLE Loss
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


chr7:1- 159,335,973 [hg38]
chr7:1- 159,335,973 [hg38]
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


chr7
chr7
Line 174: Line 174:
|Yes
|Yes
|No
|No
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


8
8
|<span class="blue-text">EXAMPLE:</span> Gain
|EXAMPLE Gain
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


chr8:1-145,138,636 [hg38]
chr8:1-145,138,636 [hg38]
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


chr8
chr8
Line 191: Line 191:
|No
|No
|No
|No
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


Common recurrent secondary finding for t(8;21) (add reference).
Common recurrent secondary finding for t(8;21) (add reference).
|}
|}


<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Individual Region Genomic Gain / Loss / LOH|The content below was from the previous version of the page. Please incorporate above.}}


Gains or amplifications of ''MYC'' (~50% of cases)<ref>{{Cite journal|last=Valera|first=Alexandra|last2=Colomo|first2=Lluis|last3=Martínez|first3=Antonio|last4=de Jong|first4=Daphne|last5=Balagué|first5=Olga|last6=Matheu|first6=Gabriel|last7=Martínez|first7=Mónica|last8=Taddesse-Heath|first8=Lekidelu|last9=Jaffe|first9=Elaine S.|date=2013-10|title=ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements|url=https://pubmed.ncbi.nlm.nih.gov/23599149|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=26|issue=10|pages=1329–1337|doi=10.1038/modpathol.2013.73|issn=1530-0285|pmc=6368829|pmid=23599149}}</ref>
Gains or amplifications of ''MYC'' (~50% of cases)<ref>{{Cite journal|last=Valera|first=Alexandra|last2=Colomo|first2=Lluis|last3=Martínez|first3=Antonio|last4=de Jong|first4=Daphne|last5=Balagué|first5=Olga|last6=Matheu|first6=Gabriel|last7=Martínez|first7=Mónica|last8=Taddesse-Heath|first8=Lekidelu|last9=Jaffe|first9=Elaine S.|date=2013-10|title=ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements|url=https://pubmed.ncbi.nlm.nih.gov/23599149|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=26|issue=10|pages=1329–1337|doi=10.1038/modpathol.2013.73|issn=1530-0285|pmc=6368829|pmid=23599149}}</ref>
Line 202: Line 202:
==Characteristic Chromosomal Patterns==
==Characteristic Chromosomal Patterns==


Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')</span>
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 212: Line 212:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE


Co-deletion of 1p and 18q
Co-deletion of 1p and 18q
Line 218: Line 218:
|No
|No
|No
|No
|<span class="blue-text">EXAMPLE:</span>
|EXAMPLE:


See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
|}
|}


<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Patterns|The content below was from the previous version of the page. Please incorporate above.}}
N/A
N/A


Line 229: Line 229:
==Gene Mutations (SNV / INDEL)==
==Gene Mutations (SNV / INDEL)==


Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 239: Line 239:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span> TP53; Variable LOF mutations
|EXAMPLE: TP53; Variable LOF mutations


<span class="blue-text">EXAMPLE:</span>
EXAMPLE:


EGFR; Exon 20 mutations
EGFR; Exon 20 mutations


<span class="blue-text">EXAMPLE:</span> BRAF; Activating mutations
EXAMPLE: BRAF; Activating mutations
|<span class="blue-text">EXAMPLE:</span> TSG
|EXAMPLE: TSG
|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
|EXAMPLE: 20% (COSMIC)


<span class="blue-text">EXAMPLE:</span> 30% (add Reference)
EXAMPLE: 30% (add Reference)
|<span class="blue-text">EXAMPLE:</span> IDH1 R123H
|EXAMPLE: IDH1 R123H
|<span class="blue-text">EXAMPLE:</span> EGFR amplification
|EXAMPLE: EGFR amplification
|
|
|
|
|
|
|<span class="blue-text">EXAMPLE:</span>  Excludes hairy cell leukemia (HCL) (add reference).
|EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).
<br />
<br />
|}
|}
Line 261: Line 261:




<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV / INDEL)|The content below was from the previous version of the page. Please incorporate above.}}
N/A
N/A


Retrieved from "https://test.ccga.io/index.php/HAEM5:ALK-positive_large_B-cell_lymphoma"